The New Class of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Has One Clear Leader and Many Followers
Summary
Inhibition of dipeptidyl peptidase IV by DPP-IV inhibitors enhances the hormone activity of GLP-1 and other bioactive peptides (GIP, PACAP38 and GRP), thereby stimulating the release of insulin and reducing the secretion of glucagon.FDA’s recent request for more clinical data to meet conditions set forth in the approvable letter of Novartis’ NDA of the DPP-IV inhibitor Galvus will aid Merck to maintain and extend its competitive edge in the field.These results were found in a search conducted by La Merie Business Intelligence and can be acquired at the Online Store PipelineReview.com.The high interest of the pharmaceutical industry in DPP-IV inhibitors reflects the market attractivity.Inhibition of dipeptidyl peptidase IV by DPP-IV inhibitors enhances the hormone activity of GLP-1 and other bioactive peptides (GIP, PACAP38 and GRP), thereby stimulating the release of insulin and reducing the secretion of glucagon.Both effects contribute to regulation of the elevated blood glucose levels in type 2 diabetic patients as measured by hemoglobin A1c (HbA1c).Available clinical data suggest that long term treatment with DPP-IV inhibitors was well tolerated with very low rates of hypoglycaemia and was not associated with weight gain or gastrointestinal disturbances.